STX-100: Phase IIa started

Biogen Idec disclosed in its 2Q12 earnings that in July it began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate weekly subcutaneous STX-100 for 8 weeks in 32 IPF patients. The tr...